relcovaptan has been researched along with Cardiomyopathy, Hypertrophic Obstructive in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barr, LA; Carter, RL; Cheung, JY; Coleman, RC; Feldman, AM; Gao, E; Grisanti, LA; Houser, SR; Koch, WJ; Li, X; Makarewich, CA; Myers, VD; Song, J; Tilley, DG; Troupes, CD; Yu, D; Zhu, W | 1 |
1 other study(ies) available for relcovaptan and Cardiomyopathy, Hypertrophic Obstructive
| Article | Year |
|---|---|
β-adrenergic receptor-mediated cardiac contractility is inhibited via vasopressin type 1A-receptor-dependent signaling.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Calcium Signaling; Cardiomyopathy, Hypertrophic; Cats; Cell Line, Tumor; Colforsin; Cyclic AMP; G-Protein-Coupled Receptor Kinases; Genes, Reporter; GTP-Binding Protein alpha Subunits, Gq-G11; Heart Failure; HEK293 Cells; Humans; Indoles; Isoproterenol; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Mutagenesis, Site-Directed; Myocardial Contraction; Pyrrolidines; Receptors, Adrenergic, beta; Receptors, Vasopressin; Recombinant Fusion Proteins; Rolipram; Second Messenger Systems | 2014 |